| 27.9 -0.41 (-1.45%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.01 | 1-year : | 39.72 |
| Resists | First : | 29.12 | Second : | 34.01 |
| Pivot price | 27.55  |
|||
| Supports | First : | 26.66 | Second : | 25.14 |
| MAs | MA(5) : | 28.05 |
MA(20) : | 27.07 |
| MA(100) : | 26.07 |
MA(250) : | 23.03 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 72.5 |
D(3) : | 73 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 29.12 | Low : | 16.54 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANIK ] has closed below upper band by 40.2%. Bollinger Bands are 52.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.61 - 28.75 | 28.75 - 28.85 |
| Low: | 27.27 - 27.46 | 27.46 - 27.58 |
| Close: | 27.63 - 27.91 | 27.91 - 28.1 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Thu, 25 Jul 2024
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - StockTitan
Wed, 24 Jul 2024
SG Americas Securities LLC Buys 627 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Tue, 23 Jul 2024
We're Not Worried About Anika Therapeutics' (NASDAQ:ANIK) Cash Burn - Yahoo Finance
Mon, 22 Jul 2024
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by Acadian Asset Management LLC - MarketBeat
Thu, 18 Jul 2024
Anika Therapeutics (NASDAQ:ANIK) Stock Price Crosses Above Two Hundred Day Moving Average of $25.17 - MarketBeat
Tue, 16 Jul 2024
ANIK - Anika Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 15 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 91.2 (%) |
| Shares Short | 733 (K) |
| Shares Short P.Month | 744 (K) |
| EPS | -5.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.06 |
| Profit Margin | -45.4 % |
| Operating Margin | -23.7 % |
| Return on Assets (ttm) | -1.9 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | 6.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.6 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | -5.33 |
| PEG Ratio | -26 |
| Price to Book value | 1.98 |
| Price to Sales | 2.4 |
| Price to Cash Flow | 239.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|